PAVmed Inc. has 12 Schedule 13D or 13G filings on record since 2025-08-14. 10 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Dana Carrera | 15.3% | 974,246 | SCHEDULE 13G/A, 2026-04-14 | 2026-03-27 |
| Ayrton Capital LLC | 9.99% | 709,069 | SCHEDULE 13G/A, 2026-05-11 | 2026-03-31 |
| Two Seas Capital LP | 9.99% | 657,219 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Scopia Holdings LLC | 9.9% | 630,118 | SCHEDULE 13G, 2026-04-13 | 2026-03-27 |
| First Manhattan Co. LLC. | 9.6% | 639,191 | SCHEDULE 13G, 2026-05-14 | 2026-03-31 |
| Nagelberg David S | 8.8% | 699,778 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Kallman Craig | 6% | 384,616 | SCHEDULE 13G, 2026-04-03 | 2026-03-27 |
| Sargent Investment Group, LLC | 5.8% | 1,006,300 | SCHEDULE 13G, 2025-08-14 | 2025-07-01 |
| Dols Scott V. | 5.4% | 346,155 | SCHEDULE 13G, 2026-04-08 | 2026-03-27 |
| Aklog Lishan | 5.1% | 369,068 | SCHEDULE 13D, 2026-04-09 | 2026-04-02 |
Purpose of Transaction (Item 4)
Aklog Lishan
Dr. Aklog acquired beneficial ownership of the shares of Common Stock described in this Schedule 13D for investment purposes. Dr. Aklog may from time to time acquire beneficial ownership of additional securities for investment purposes, or dispose of securities, in the open market or in private transactions, including upon exercise of options described below and subject to the restricted stock agreements described below. At the date of this Schedule 13D, except as set forth in this Schedule 13D, and as consistent with Dr. Aklog's position as Chairman and Chief Executive Officer of the Issuer, Dr. Aklog has no plans or proposals which would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of the board of directors or management of the Issuer; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-09; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Sargent Investment Group, LLC | 5.8% | SCHEDULE 13G |
| 2026-04-03 | Tasso Partners, LLC | 14.3% | SCHEDULE 13G/A |
| 2026-04-03 | Kallman Craig | 6% | SCHEDULE 13G |
| 2026-04-08 | Dols Scott V. | 5.4% | SCHEDULE 13G |
| 2026-04-08 | Nagelberg David S | 8.6% | SCHEDULE 13G |
| 2026-04-09 | Aklog Lishan | 5.1% | SCHEDULE 13D |
| 2026-04-13 | Scopia Holdings LLC | 9.9% | SCHEDULE 13G |
| 2026-04-14 | Dana Carrera | 15.3% | SCHEDULE 13G/A |
| 2026-05-11 | Ayrton Capital LLC | 9.99% | SCHEDULE 13G/A |
| 2026-05-14 | First Manhattan Co. LLC. | 9.6% | SCHEDULE 13G |
| 2026-05-15 | Two Seas Capital LP | 9.99% | SCHEDULE 13G |
| 2026-08-13 | Nagelberg David S | 8.8% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for PAVmed Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.